

Summary of Safety and Effectiveness

Prepared in accordance with 21 CFR Part 807.92(c)

1. Submitter Information

JAN 2 8 2005

a. Submitter:

Kontron Medical SAS 52, rue Pierre Curie 78373 Plaisir, Yveline

France

b. Contact Person:

Ms. Georgina Fabian Kontron Medical LLC. 9j Brookside Heights Wanaque, NJ 07465 Phone: 973-839-8669

c. Date Prepared:

15 September 2004

2. Name of device

a. Trade name:

Sigma 5000 series, Imagic

b. Common name:

Medical Diagnostic Ultrasound Imaging System and transduc-

ers

c. Classification name:

Ultrasonic Pulsed Doppler Imaging System 21 CFR 892.1550

90-IYN

Ultrasonic Pulsed Echo Imaging System 21 CFR 892.1560

90-IYO

Diagnostic Ultrasonic Transducer 21 CFR 892.1570 90-ITX

3. Equivalent Legally-Marketed Devices:

Kontron Medical Sigma 110/330, K002239

The technological characteristics of the predicate device are the same as those of the new device.

4. Description

The Sigma 5000 series, Imagic is an ultrasound instrument intended to perform the following diagnostic ultrasound investigations: Imaging (B-mode), Time motion (M-mode), Pulsed wave Doppler (PW Doppler), Continuous wave Doppler (CW Doppler), Color Flow Mapping (CFM) and Color Time motion (CM mode).

The submission also includes the transducers necessary for these procedures.

The system is a mobile console approximately 60 cm wide, 95 cm deep and 130 cm high equipped with a keyboard control panal, a large TFT screen, assorted transducers and image storage or hard-copy devices



5. Intended use

Diagnostic ultrasound investigations: Imaging (B-mode), Time motion (M-mode), Pulsed wave Doppler (PW Doppler), Continous wave Doppler (CW Doppler), Color Flow Mapping (CFM) adn Color Time motion (CM mode).

6. Performance Data

- a. Non-clinical tests: The device has been evaluated for acoustic output, biocompatibility and thermal, electrical and mechanical safety, and has been found conform with applicable medical device safety standards.
- b. Clinical tests: Since the Sigma 5000 series Imagic uses the same technology and principles as existing devices, clinical tests are not required.
- c. Conclusion: Intended uses and other key features are consistent with traditional clinical practice, FDA guidelines and established methods of patient examination. The design and development process of the manufacturer conforms with 21 CFR 820 Quality System Regulation and ISO13485 quality system standards. The product is designed to conform with applicable medical device safety standards and compliance is verified through independent evaluation with ongoing factory surveillance. Diagnostic ultrasound has accumulated a long history of safe and effective performance. Therefore it is the opinion of Kontron Medical that the Sigma 5000 series Imagic is substantially equivalent with respect to safety and effectiveness to devices currently cleared for market.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Kontron Medical S.A.S. % Mr. Robert Mosenkis President CITECH Medical Device Testing and Consulting 5200 Butler Pike PLYMOUTH MEETING PA 19462-1298

JAN 2 8 2005

Re: K050099

Trade Name: Sigma 5000 Series, Imagic Ultrasound System

Regulation Number: 21 CFR 892.1550

Regulation Name: Ultrasonic pulsed doppler imaging system

Regulation Number: 21 CFR 892.1560

Regulation Name: Ultrasonic pulsed echo imaging system

Regulation Number: 21 CFR 892.1570

Regulation Name: Diagnostic ultrasonic transducer

Regulatory Class: II

Product Code: 90 IYN, IYO, and ITX

Dated: January 17, 2005 Received: January 18, 2005

Dear Mr. Mosenkis:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

This determination of substantial equivalence applies to the following transducers intended for use with the Sigma 5000 Series, Imagic Ultrasound System, as described in your premarket notification:

<u>Transducer Model Number</u>

2-4 PA 2-5 CA 5-12 LA 3-8 PA 3-8 TEM 2 MHz Pen 8 MHz Pen

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This determination of substantial equivalence is granted on the condition that prior to shipping the first device, you submit a postclearance special report. This report should contain complete information, including acoustic output measurements based on production line devices, requested in Appendix G, (enclosed) of the Center's September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers." If the special report is incomplete or contains unacceptable values (e.g., acoustic output greater than approved levels), then the 510(k) clearance may not apply to the production units which as a result may be considered adulterated or misbranded.

The special report should reference the manufacturer's 510(k) number. It should be clearly and prominently marked "ADD-TO-FILE" and should be submitted in duplicate to:

Food and Drug Administration Center for Devices and Radiological Health Document Mail Center (HFZ-401) 9200 Corporate Boulevard Rockville, Maryland 20850

This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small

Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

If you have any questions regarding the content of this letter, please contact Rodrigo C. Perez at (301) 594-1212.

Sincerely yours,

Manay C Broadon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure(s)



System: Sigma 5000 series, Imagic

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

						Mode	of Operation			
Clinical Application	A	В	М	PW D	CW D	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal		N	N	N		N	N		N	
Abdominal		N	N	N		N	N		N	
Intraoperative (specify)										
Intraoperative Neuro- logical										
Pediatric		N	N	N		N	N		N	
Small organs (specify)		N	N	N		N	N		N	
Neonatal Cephalic										
Adult Cephalic										
Cardiac		N	N	N	N	N	N		N	
Transesophageal		N	N	N	N	N	N		N	
Transrectal										
Transvaginal						•••				
Transurethral										
Intravascular										
Peripheral Vascular		N	N	N	N	N	N		N	
Laparascopic										
Musculo-skeletal Conventional		N	N	N		N	N		N	
Musculo-skeletal Super- ficial		N	N	N		N	N		N	
Other (specify)								<u> </u>		

N= new indication; P= previously cleared by FDA; E= added under Appendix E

Additional Comments:

• Small organs: Thyroid, Breast, Testicle

• Combined modes: B + M, B + PWD, Color Doppler + PWD, Amplitude Doppler + PWD

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

(Division Sign-Off)

Division of Reproductive, Abdominal, and Radiological Devices

Sigma 5000 series, IMAGIC : Summary of Safety and Effectiveness 15 Sept 04



System: Sigma 5000 series, Imagic

Transducer: 2-4 PA

	Mode of Operation												
Clinical Application	A	В	М	PW D	CW	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)			
Ophthalmic													
Fetal													
Abdominal													
Intraoperative (specify)													
Intraoperative Neuro- logical							-						
Pediatric				<u> </u>					ļ				
Small organs (specify)													
Neonatal Cephalic													
Adult Cephalic				<u> </u>									
Cardiac		N	N	N	N	N	N		N				
Transesophageal	<u> </u>			ļ						ļ			
Transrectal					ļ <u>.</u>					<u> </u>			
Transvaginal				ļ									
Transurethral			ļ	ļ	ļ								
Intravascular				<u>.</u>	ļ								
Peripheral Vascular		<u> </u>		ļ	ļ								
Laparascopic		<u> </u>							<u> </u>				
Musculo-skeletal Conventional													
Musculo-skeletal Super- ficial													
Other (specify)													

N= new indication; P= previously cleared Additional Comments:	by FDA; E= added under Appendix E
	or Doppler + PWD, Amplitude Doppler + PWD
Combined modes. B + M, B + 1 WB, Co.	or Dopples + 1 + D, the property of the proper
Concurrence of CDRH, Office of Device I	Evaluation (ODE)
,	- Vansyl Broadon
Prescription Use (Per 21 CFR 801.109)	(Division Sign-Off)
	Division of Reproductive, Abdominal,
	and Radiological Devices KO50099
	510(k) Number <u> </u>



System: Sigma 5000 series, Imagic Transducer: 2-5 CA

					•	Mode	of Operation			
Clinical Application	A	В	М	PW D	CW D	Color Doppler	Amplitude Doppler	Color Velocity Imaging	C'ombined (specify)	Other (specify)
Ophthalmic										
Fetal		N	N	N		N	N		N	
Abdominal		N	N	N		N	N		N	
Intraoperative (specify)										
Intraoperative Neuro- logical										
Pediatric		N	N	N		N	N		N	
Small organs (specify)										·
Neonatal Cephalic										····
Adult Cephalic										
Cardiac										
Transesophageal						·				
Transrectal					·					·
Transvaginal										
Transurethral									-	
Intravascular										
Peripheral Vascular										
Laparascopic										
Musculo-skeletal Conventional										
Musculo-skeletal Super- ficial										
Other (specify)										

N= new indication; P= previously cleared	by FDA; E= added under Appendix E
Additional Comments:	
• Combined modes: B + M, B + PWD, Co	olor Doppler + PWD, Amplitude Doppler + PWD
Concurrence of CDRH, Office of Device	Evaluation (ODE) ———————————————————————————————————
Prescription Use (Per 21 CFR 801.109)	(Division Sign-Off) Division of Reproductive, Abdominal, and Radiological Devices 510(k) Number



System: Sigma 5000 series, Imagic Transducer: 5-12 LA

	Mode of Operation												
Clinical Application	A	В	м	PW D	CW D	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)			
Ophthalmic													
Fetal										-			
Abdominal		N	Z	N		N	N		N				
Intraoperative (specify)													
Intraoperative Neuro- logical			_										
Pediatric		N	N	N		N	N		N				
Small organs (specify)		N	N	N		N	N		N				
Neonatal Cephalic					<u> </u>								
Adult Cephalic				<u> </u>									
Cardiac		N	N	N	N	N	N		N				
Transesophageal			ļ. <u> </u>	ļ									
Transrectal				ļ	ļ								
Transvaginal													
Transurethral	<u> </u>		<u> </u>				<u> </u>			1			
Intravascular		<u>L</u>		<u> </u>	<u> </u>								
Peripheral Vascular		N	N	N	N	N	N		N				
Laparascopic				<u> </u>									
Musculo-skeletal Conventional		N	N	N		N	N		N				
Musculo-skeletal Super- ficial		N	N	N		N	N		N				
Other (specify)					1								

N= new indication; P= previously cleared b	ov EDA: E= added under Appendix E
N= new indication; P= previously cleared of	y IDA, E= added and reponder 2
Additional Comments:	
• Small organs: Thyroid, Breast, Testicle	
• Combined modes: B + M, B + PWD, Colo	r Doppler + PWD, Amplitude Doppler + PWD
Comonica modes. S 1 114 S 12 11 = 4 11	
Concurrence of CDRH, Office of Device E	valuation (ODE) Janey & Broakon
Prescription Use (Per 21 CFR 801.109)	(Division Sign-Off) Division of Reproductive, Abdominal,
	and Radiological Devices 20500 89



System: Sigma 5000 series, Imagic Transducer: 3-8 PA

	Mode of Operation												
Clinical Application	A	В	М	PW D	CW D	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)			
Ophthalmic	-												
Fetal													
Abdominal													
Intraoperative (specify)										·			
Intraoperative Neuro- logical									ļ				
Pediatric		N	N	N	N	N	N		N				
Small organs (specify)													
Neonatal Cephalic				<u> </u>	ļ. <u>.</u>								
Adult Cephalic				<u> </u>	<u> </u>								
Cardiac		N	N	N	N	N	N		N				
Transesophageal			<u> </u>					<u> </u>	<u> </u>				
Transrectal													
Transvaginal	ļ												
Transurethral	<u> </u>												
Intravascular										ļ			
Peripheral Vascular					<u> </u>								
Laparascopic									<u> </u>	<u> </u>			
Musculo-skeletal Conventional													
Musculo-skeletal Super- ficial													
Other (specify)													

N= new indication; P= previously cleared Additional Comments:	
• Combined modes: B + M, B + PWD, Col	for Doppler + PWD, Amplitude Doppler + PWD
Concurrence of CDRH, Office of Device	Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)	Marcy Chordor (Division Sign-Off)
	Division of Reproductive, Abdominal, and Radiological Devices KD50099



System: Sigma 5000 series, Imagic

Transducer: 3-8 TEM

	Mode of Operation												
Clinical Application	٨	В	М	PW D	CW D	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)			
Ophthalmic									ļ				
Fetal													
Abdominal				<u> </u>									
Intraoperative (specify)							<u> </u>						
Intraoperative Neuro- logical													
Pediatric													
Small organs (specify)					ļ				<u> </u>				
Neonatal Cephalic				<u> </u>									
Adult Cephalic													
Cardiac		N	N	N	N	N	N		N				
Transesophageal		N	N	N_	N_	N_	N		N	ļ			
Transrectal				<u> </u>	<u> </u>		<u> </u>			ļ			
Transvaginal			<u></u>		<u> </u>		ļ						
Transurethral	<u> </u>							-					
Intravascular				<u> </u>					<u> </u>				
Peripheral Vascular	 		ļ	ļ	ļ	_							
Laparascopic		ļ		<u> </u>	ļ				ļ				
Musculo-skeletal Conventional					<u> </u>								
Musculo-skeletal Super- ficial													
Other (specify)						<u> </u>				_			

N= new indication; P= previously cleared	by FDA; E= added under Appendix E
Additional Comments:	
• Combined modes: B + M, B + PWD, Col-	or Doppler + PWD, Amplitude Doppler + PWD
Concurrence of CDRH, Office of Device I	Evaluation (ODE)
Prescription Use (Pcr 21 CFR 801.109)	(Division Sign-Off) Division of Reproductive, Abdominal,
	and Radiological Devices K0300.99



System: Sigma 5000 series, Imagic Transducer: 2 MHz Pen

	Mode of Operation												
Clinical Application	A	В	М	PW D	CW D	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)			
Ophthalmic													
Fetal									ļ				
Abdominal													
Intraoperative (specify)													
Intraoperative Neuro- logical	•												
Pediatric													
Small organs (specify)													
Nconatal Cephalic													
Adult Cephalic													
Cardiac				N	N		<u> </u>						
Transesophageal					ļ								
Transrectal				<u> </u>									
Transvaginal				ļ	ļ	ļ	<u> </u>						
Transurethral				l									
Intravascular			<u> </u>	ļ <u>.</u>						ļ			
Peripheral Vascular			ļ		ļ		_			<u> </u>			
Laparascopic				1					ļ				
Musculo-skeletal Conventional													
Musculo-skeletal Super- ficial													
Other (specify)													

N= new indication; P= previously cleared b	y FDA; E= added under Appendix E			
Additional Comments:				
Concurrence of CDRH, Office of Device Evaluation (ODE)				
Prescription Use (Per 21 CFR 801.109)	Mancy Chodon (Division Sigh-Off) Division of Reproductive, Abdominal, and Radiological Devices 510(k) Number			



System: Sigma 5000 series, Imagic Transducer: 8 MHz Pen

Clinical Application			-			Mode	of Operation			
	۸	В	М	PW D	CW D	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal										
Abdominal			<u></u>	<u> </u>						
Intraoperative (specify)										
Intraoperative Neuro- logical						·				
Pediatric				<u></u>						
Small organs (specify)									<u> </u>	
Neonatal Cephalic										
Adult Cephalic			ļ <u>.</u>						ļ	
Cardiac			<u> </u>	<u>.</u>						
Transesophageal		ļ	<u> </u>							
Transrectal		<u> </u>					<u> </u>	!		
Transvaginal										
Transurethral		<u> </u>	<u> </u>							
Intravascular					<u> </u>					
Peripheral Vascular			<u> </u>	N	N					
Laparascopic							<u> </u>			ļ
Musculo-skeletal Conventional										
Musculo-skeletal Super- ficial										
Other (specify)										

N= new indication; P= previously cleared by	y FDA; E= added under Appendix E			
Additional Comments:				
Concurrence of CDRH, Office of Device Evaluation (ODE)				
	Nancy C Grogdon			
Prescription Use (Per 21 CFR 801.109)	(Division Sign-Off)			
	Division of Reproductive, Abdominal,			
	ars Padiological Devices K050099			
	5 Filiky Number			